medscape semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach Medscape | Topline results from

Abstract Human GLP-1 (glucagon-like peptide-1) can produce a remarkable improvement in glycemic control in patients with type 2 diabetes

Wellness & Weight Loss Programs: Frequently used in injection clinics for metabolism and wellness support

Can spironolactone raise my potassium to a dangerous level

I am worried about being on medication long-term. This is an understandable concern, but it should be weighed against the documented health consequences of obesity

People with higher starting BMI Individuals with BMI above 40 often see faster absolute weight loss in the early phases, simply because a higher body weight means a larger caloric expenditure even at rest, and the same percentage reduction in food intake creates a larger absolute caloric deficit

This is also the phase where lifestyle factors become most important